The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds

We show in this paper the contribution of the whole Raman spectrum including the phonon spectrum, to detect, identify and characterize polymorphic forms of molecular compounds, and study their stability and transformation. Obtaining these kinds of information is important in the area of pharmaceutic...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2011-09, Vol.417 (1), p.17-31
Main Authors: Hédoux, Alain, Guinet, Yannick, Descamps, Marc
Format: Article
Language:English
Subjects:
Caffeine
Caffeine - chemistry
Chemistry, Pharmaceutical - methods
Crystallization - methods
Drug Stability
environmental factors
Indomethacin
Indomethacin - chemistry
ingredients
Pharmaceutical Preparations - analysis
Pharmaceutical Preparations - chemistry
Phase Transition
Phonon Raman spectrum
Polymorphic transformations
Povidone - chemistry
Raman spectroscopy
Spectrum Analysis, Raman - methods
Vibrational density of states
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We show in this paper the contribution of the whole Raman spectrum including the phonon spectrum, to detect, identify and characterize polymorphic forms of molecular compounds, and study their stability and transformation. Obtaining these kinds of information is important in the area of pharmaceutical compounds. Two different polymorphic systems are analyzed through investigations in indomethacin and caffeine exposed to variable environmental conditions and various stresses, as possibly throughout the production cycle of the active pharmaceutical ingredient. It is shown the capability of the low-frequency Raman spectroscopy to reveal disorder in the crystalline state, to detect small amorphous or crystalline material, and to elucidate ambiguous polymorphic or polyamorphic situations.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2011.01.031